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Abstract
It has been hypothesized that cellular damage caused by oxidative stress is associated with late-life depression but
epidemiological evidence is limited. In the present study we evaluated the association between urinary 8-iso-prostaglandin
F2a (8-iso-PGF2a), a biomarker of lipid peroxidation, and depressed mood in a large sample of community-dwelling older
adults. Participants were selected from the Health, Aging and Body Composition study, a community-based longitudinal
study of older persons (aged 70–79 years). The present analyses was based on a subsample of 1027 men and 948 women
free of mobility disability. Urinary concentration of 8-iso-PGF2a was measured by radioimmunoassay methods and adjusted
for urinary creatinine. Depressed mood was defined as a score greater than 5 on the 15-item Geriatric Depression Scale and/
or use of antidepressant medications. Depressed mood was present in 3.0% of men and 5.5% of women. Depressed men
presented higher urinary concentrations of 8-iso-PGF2a than non-depressed men even after adjustment for multiple
sociodemographic, lifestyle and health factors (p = 0.03, Cohen’s d = 0.30). This association was not present in women
(depressed status-by-sex interaction p= 0.04). Our study showed that oxidative damage may be linked to depression in
older men from a large sample of the general population. Further studies are needed to explore whether the modulation of
oxidative stress may break down the link between late-life depression and its deleterious health consequences.
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Introduction
Depression is highly prevalent in older persons and may
complicate concurrent clinical conditions and increase the risk of
disability and mortality [1]. The underlying pathophysiological
mechanisms for this well-established association remain elusive.
Recent preclinical and clinical observations suggest that a
potential role may be played by oxidative stress [2], in which
production of highly reactive oxygen species (ROS) overwhelms
antioxidant defenses in the cell and damage biomolecules (lipids,
proteins, DNA) leading to mitochondrial dysfunction and cell
death. Neurons are highly sensitive to oxidative stress due to their
high metabolic rate and oxidative damage has been implicated in
age-related neuronal decrement and neurodegenerative diseases
[3–5]. Depression may be hypothesized to be a direct consequence
of neurodegenerative processes. Indeed, brain imaging studies
have linked depression with structural and functional alterations of
limbic and cortical structures, particularly in the hippocampus [6].
Another hypothesis is that oxidative stress may impact on
depression determinants. For instance, products of lipid peroxi-
dation (such as isoprostanes) increase with age and are associated
with multiple contributors to depression, such as cardiovascular
disorders [7;8], obesity [9], stroke [10], diabetes [11], and
inflammation [12]. Finally, oxidative stress may be also the
consequence of depression, because depressed persons are more
likely to engage in behaviors known to increase oxidative stress,
such as smoking, excessive alcohol use, poor nutrition and
sedentariness [13;14].
Research investigating the association between depression and
oxidative damage is a relatively new area of study, and
epidemiological evidence is limited. The few preliminary clinical
studies have documented the association of depression with several
biomarkers of protein (malondialdehyde [MDA]) [15;16], DNA
(8-hydroxy-29deoxyguanosine [8-OHdG]) [17;18], and lipid [19–
21](8-iso-prostaglandin F2a [8-iso-PGF2a]) oxidation. Neverthe-
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less, existing studies characterized by small sample sizes have
limited capacity to adequately take into account potential
confounders and/or to perform secondary analyses in specific
subgroups.
It has been proposed that biomarkers of lipid peroxidation may
transduce the effect of oxidative stress associated with metabolic
disturbances into specialized forms of cellular activation [13].
Previous epidemiological studies suggested that metabolic alter-
ations (e.g. abdominal obesity, leptin dysregulation and inflam-
matory responses) were associated with late-life depression
especially in men [22–24]. Moreover, data from the Health,
Aging and Body Composition (Health ABC) study confirmed
different immuno-metabolic profiles, due to difference in specific
adipose depots, across gender/race groups [25;26].
Using data from Health ABC, we hypothesized that urinary
concentrations of isoprostanes might be independently related
with depressed mood in older persons. Thus, we examined the
association between urinary excretion of 8-iso-PGF2a and
depressed mood in a large cohort of community-dwelling older
persons taking important sociodemographic, health and lifestyle
factors into account. Moreover, we explored whether this
association differs according to gender and race.
Methods
Study Population
Data are from the Health, Aging and Body Composition
(Health ABC) study, a cohort study consisting of 3075 initially
well-functioning, community-dwelling persons aged 70 to 79 years
at the baseline visit (1997–1998). Participants were identified from
a random sample of white Medicare beneficiaries and all age-
eligible community-dwelling black residents in designated areas
surrounding Memphis, TN, and Pittsburgh, PA. Participants were
considered eligible if they reported no difficulty walking one
quarter of a mile, going up 10 steps without resting, and
performing basic activities of daily living. Exclusion criteria
included history of active treatment for cancer in the prior 3
years, plans to move out of the study area in the next 3 years, or
participation in a randomized trial of a lifestyle intervention. Key
components of Health ABC included an in-person interview and
clinic-based examination, with evaluation of body composition,
health conditions, and physical functioning. The primary
measures were repeated at each annual clinic visit. The
Institutional Review Boards at the University of Tennessee and
at the University of Pittsburgh approved The Health ABC
research protocol and the present study. Each participant signed
an informed consent form. All clinical investigation has been
conducted according to the principles expressed in the Declaration
of Helsinki.
For the present analyses, we used cross-sectional data from the
second visit (or first annual follow-up visit; 1998–1999) when
urinary excretion of 8-iso-PGF2a was ascertained as part of an
ancillary research project examining the predictive value of this
biomarker for the development of mobility disability [27].
Therefore, from the original Health ABC study sample, 32
participants who died during the first year, 648 who developed
mobility disability before the analytical baseline and 111 who had
missing or inadequate biological specimens were excluded.
Excluded participants were older, more likely to be women and
had higher prevalence of diabetes and cardiovascular disorders at
the baseline visit [27]. Moreover, we excluded other 34
participants with missing data on depressive symptoms. Thus,
the present analyses were based on the remaining 1975
participants.
Depressed Mood
Depressed mood was operationally defined by the presence of
relevant depressive symptoms and/or antidepressant use. Depres-
sive symptoms were evaluated using the 15-item version of the
Geriatric Depression Scale (GDS-15) [28]. Originally intended for
screening depression in a population of non-demented elderly, it
has shown adequate psychometric properties in community,
primary care and hospital settings [29]. Items are summed and
greater scores indicate a greater number of depressive symptoms.
The GDS-15 does not contain items concerning somatic
complaints. Presence of significant depressive symptoms was
defined by the established cut-point of .5, which has a sensitivity
of 90.9%, a specificity of 64.5%, a positive predictive value of
73.2% and a negative predictive value of 86.9% with respect to
validated psychiatric diagnoses in elderly patients [30].
All medications regularly taken in the past 2 weeks were
recorded according to the Iowa Drug Information System [31].
Antidepressant use (with depression/mood as self-reported indi-
cation) included monoamine-oxidase inhibitors (MAO-I), tricyclic
antidepressants (TCA), selective serotonin reuptake inhibitors
(SSRI), and other antidepressants.
8-iso-prostaglandin F2a
Measurement of the urinary excretion of 8-iso-PGF2a has been
demonstrated to be a reliable marker of lipid peroxidation in vivo
[32]. Morning spot urine samples were collected from participants
at their second annual clinical visit and stored at 270uC for
subsequent analyses. Urinary concentrations of 8-iso-PGF2a were
measured by previously validated radioimmunoassay (RIA)
methods [33] at the Laboratory of Clinical Pharmacology of
Eicosanoids and Pharmacodynamic located in the Center of
Excellence on Aging at the ‘‘Gabriele D’Annnunzio’’ University
Foundation (Chieti, Italy). Measurements of urinary eicosanoid
metabolites by RIA methods have been validated with different
antisera and by comparison with gas chromatography-mass
spectrometry [33]. The intra-assay and inter-assay coefficients of
variation for the 8-iso-PGF2a were 2.0% and 2.9% at the lowest
level of standard (2 pg/ml), and 3.7% and 10.8% at the highest
level of standard (250 pg/ml), respectively. Urinary levels of 8-iso-
PGF2a were adjusted for urinary creatinine (median: men 0.80 and
women 0.56 mg/mL; p,.0001) to account for differences in renal
excretory function. In the present analyses, concentration of 8-iso-
PGF2a was considered as a continuous measure as well as a
dichotomous categorical variable (defined by the highest sex-
specific quartiles; i.e., higher than 926.7 pg/mg-creatinine for
men, and higher than 1,175.4 pg/mg-creatinine for women).
Covariates
Covariates were a priori selected on the basis of previously
reported associations with depression and oxidative stress.
Sociodemographic variables included age, sex, race, educational
attainment. Because a difference in median 8-iso-PGF2a across
study sites was found (Memphis 746.8 vs Pittsburgh 689.9 pg/mg-
creatinine, Kruskall-Wallis p=0.01), this covariate was retained in
multivariate analyses. Alcohol consumption was assessed using a
standardized questionnaire [34] and categorized as never, ,1
drink/week, 1–7 drinks/week and .7 drinks/week. Body mass
index (BMI) was calculated as kg/m2 and categorized as normal
(BMI,25), overweight (25–29.99) and obese (BMI $30). Presence
of cardiovascular diseases (CVD: heart failure, myocardial
infarction, angina pectoris, coronary angioplasty or coronary
artery bypass grafting), cerebrovascular diseases (stroke or
transient ischemic attack) and diabetes were specifically ascer-
tained using standardized algorithms [35], considering various
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information including self-report, medications, clinical findings,
and medical claims data from the former Health Care Financing
Administration. Each disease variable was then updated taking
into account the new diagnoses and events reported by partici-
pants or determined by review of clinical documentation in the
year prior to the second visit (the present study baseline). Since
smoking status, comprehensive physical activity participation and
cognitive function were not assessed at the second visit, these
variables derive from data collected at the first Health ABC study
visit. These dimensions are less likely to change during a 1-year
period in this sample of well-functioning older persons [36;37].
Smoking status was coded as non-smoker/former/current smoker.
Physical activity (in kcal/kg/week) was estimated through a
specific questionnaire on the basis of to time/intensity spent on
physical activities [38]. Cognitive status was evaluated with the
Modified Mini Mental State Examination (3MS) [39].
Statistical Analyses
Variables are presented as percentages, means (and standard
deviations, SD) or median (and interquartile range, IQR).
Univariate differences in sample characteristics were tested using
chi-square or Kruskal-Wallis ANOVA, as appropriate. Differences
in adjusted means of 8-iso-PGF2a across depression status were
examined using analyses of co-variance. For significant differences
Cohen’s d [40] was calculated as a measure of effect size. In these
analyses, concentrations of 8-iso-PGF2a were log-transformed due
to skewed distribution and mean values were presented back-
transformed to facilitate interpretation. To investigate possible sex
and race differences, depression status-by-sex and depression
status-by-race interaction terms were entered in models including
terms for depression status, age, sex, race, site, and education.
Odds Ratios (ORs) and 95% Confidence Intervals (95%CI) of
presenting depressed mood according to 8-iso-PGF2a levels were
estimated using logistic regression models. Analyses were adjusted
for sociodemographic factors (age, race, education and site) and
additionally adjusted for all the confounders (alcohol, smoking,
3MS, physical activity, BMI, cerebrovascular and cardiovascular
disease and diabetes). Significance level was set at p,0.05. Because
a statistically significant depression status-by-sex interaction was
found, all results are shown for men and women separately. All
analyses were performed using SAS (v. 9.2, SAS Institute, Inc.,
Cary, NC).
Table 1. Main characteristics of the study population.
Total sample Men Women
Characteristics (n = 1975) (n = 1027) (n = 948) pa
Age (years) (mean6SD) 74.662.9 74.962.9 74.662.8 0.02
Site (Memphis)(%) 49.7 49.0 50.5 0.50
Race (Black) (%) 35.7 32.5 39.0 0.003
Education (%) ,0.0001
less than high school 20.8 23.5 17.8
high school 31.8 25.2 39.1
postsecondary 47.4 51.4 43.2
Alcohol intake (%) ,0.0001
never 47.5 41.8 54.4
,1 drink/wk 21.2 20.3 22.1
1–7 drink/wk 23.2 26.3 20
.7 drink/wk 8.1 12.4 3.6
Smoking status (%) ,0.0001
never smoker 44.7 31.7 58.8
former smoker 46.9 9.1 7.7
current smoker 8.4 59.2 33.5
Physical activity (Kcal/kg/week)(mean6SD) 86.9668.9 87.4672.6 86.4664.6 0.26
Modified Mini Mental State Examination (mean6SD) 90.968.0 90.068.4 91.867.5 ,0.0001
Diabetes (%) 12.2 14.1 10.0 0.01
Cardiovascular disease (%) 15.7 21.5 9.4 ,0.0001
Cerebrovascular disease (%) 6.0 5.9 6.0 0.95
Body mass index (%) ,0.0001
normal 34.5 30.4 38.9
overweight 44.2 50.2 37.7
obesity 21.3 19.4 23.4
Depressed mood (%) 4.2 3.0 5.5 0.01
8-iso-PGF2a (pg/mg-creat.)(median and IQR) 721.3 (467.3–1052.3) 633.4 (420.1–929.4) 800.5 (533.5–1178.9) ,0.0001
afrom chi-square test or Kruskal-wallis ANOVA.
doi:10.1371/journal.pone.0065406.t001
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Figure 1. Adjusted means (and standard errors) of 8-iso-PGF2a according to depression group in men and women. Values were
adjusted for age, race, education, site, alcohol use, smoking, 3MSE, physical activity, BMI, cerebrovascular disease, CVD and diabetes. Statistical
significance from analyses based on log-transformed 8-iso-PGF2a due to skewed distribution.
doi:10.1371/journal.pone.0065406.g001
Figure 2. Plot of (log)8-iso-PGF2a concentrations versus adjusted predicted probability of depressed mood according to sex.
Predicted probability and 95% Confidence Intervals (95%CIs) are adjusted for age, race, education, site, alcohol use, smoking, 3MSE, physical activity,
BMI, cerebrovascular disease, CVD and diabetes.
doi:10.1371/journal.pone.0065406.g002
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Results
Main characteristics of the study sample are shown in Table 1.
Participants’ mean age was 74.6 (SD 2.9) years; 48.0% of
participants were women, and 35.7% black. The median level of
8-iso-PGF2a was 721.3 (IQR 467.3–1052.3) pg/mg-creatinine.
The overall prevalence of depressed mood was 4.2% (GDS-15
greater than 5:1.4%; antidepressant use: 2.6%; both: 0.2%).
Almost half of the sample (43.3%) had a GDS-15 score of 0.
Participants on antidepressants, as compared to those drug-free,
had significantly higher GDS-15 scores (1.9, SD 1.8 vs 1.1, SD 1.4;
p=0.001). Men, as compared to women, were older and less
educated, had a lower cognitive function, and were more likely to
drink alcohol, to smoke and to have diabetes and cardiovascular
disorders. Moreover, men had lower concentrations of 8-iso-
PGF2a (median 633.4, IQR 420.1–929.4 vs 800.5, IQR 533.5–
1178.9 pg/mg-creatinine; p,0.001) and a lower prevalence of
depressed mood (3.0% vs 5.5%; p=0.01).
After adjustment for sociodemographic factors, no statistically
significant differences in 8-iso-PGF2a levels were found between
participants with depressed mood and those in the comparison
group. However, a significant depression-by-sex interaction
(p=0.04) was found, whereas the depression-by-race interaction
term was not statistically significant (p=0.21). Figure 1 shows
adjusted means (and standard errors) of 8-iso-PGF2a according to
depression status in men and women. Men with depressed mood
had higher 8-iso-PGF2a concentrations compared to non-
depressed men, even after adjustment for multiple potential
confounders (907.7, SE 95.2 vs 752.9, SE 16.2 pg/mg-creatinine,
p=0.03, Cohen’s d = 0.30). In contrast, no differences in 8-iso-
PGF2a were found in women with respect to presence of depressed
mood (935.3, SE 82.2 vs 948.3 SE 19.7 pg/mg-creatinine,
p=0.51). In men, to test for a dose-response relationship we
divided non-depressed participants into three groups according to
GDS-15 scores selecting cut-off points to create subgroups with at
least the same number of subjects as the depressed group. In a fully
adjusted model of analysis of covariance we found a trend
(p = 0.08) in the adjusted means of 8-iso-PGF2a across the different
groups (depressed: 907.9 pg/mg-creatinine; GDS-15 score 4–
5:854.2 pg/mg-creatinine: GDS-15 score 1–3:732.3 pg/mg-cre-
atinine; GDS-15 score 0:766.1 pg/mg-creatinine).
Table 2 shows the (adjusted) ORs of being depressed separately
in men and women. After full adjustment, higher concentrations of
8-iso-PGF2a were significantly associated with depressed mood in
men (OR=2.06, 95%CI= 1.09–3.89, p=0.03), but not in women
(OR=0.87, 95%CI= 0.56–1.36, p=0.53). Adjusted predicted
probability of having depressed mood according to (log)8-iso-
PGF2a in men and women are plotted in Figure 2. Consistent
results were obtained in analyses distinguishing participants with
high (i.e. highest sex-specific quartile) versus normal (i.e. lower
three quartiles) levels of 8-iso-PGF2a. Finally, similar results were
obtained in sensitivity analyses performed after the exclusion of
107 participants with baseline cognitive impairment as indicated
by a 3MS score below 80 [41] (data not shown).
Discussion
The present study examined the association between a
biomarker of oxidative damage and depressed mood in a large
sample of community-dwelling older persons. After taking into
account a large set of possible confounding factors, our analyses
found the presence of a sex-specific relationship between urinary
concentrations of 8-iso-PGF2a and depressed mood. Depressed
men showed higher levels of 8-iso-PGF2a compared with non-
depressed men. This association was of medium effect size,
comparable to those found for inflammatory markers [42], brain-
derived neurotrophic factor [43] and cortisol [44]. In contrast, no
significant association was found in women.
In the present study only a small percentage of participants were
classified as having depressed mood and almost half of the sample
did not report any depressive symptoms. This may be due to the
fact that the present analyses was based on a sub-sample from the
Health ABC study [27] of non-disabled and well-functioning
participants, therefore less likely to experience psychological
distress. This is in contrast with the high prevalence of depressive
syndromes commonly reported in older persons [1]. On the other
hand, the selection of such persons decreases the probability that
the association between depressed mood and oxidative damage
may be biased by important confounding factors in late-life such as
chronic diseases and disability.
The reasons for the lack of association in the present study
between a measure of oxidative damage and depressed mood in
women are unclear. Interestingly, we found that men, as
compared to women, had lower levels of 8-iso-PGF2a and less
depressed mood. However, men were more likely to present
characteristics associated with both oxidative stress and depres-
sion, such as smoking, cardiovascular diseases and diabetes.
Gender differences in body composition may also have a role: men
have more visceral fat, which is a major contributor to pathogenic
immuno-metabolic responses linked to metabolic diseases and
depression, while women have more subcutaneous fat, which has
been associated to a more favorable immuno-metabolic profile
[25;26]. It has been proposed indeed that F2-isoprostanes may
transduce the effect of oxidative stress associated with complex
metabolic disorders into specialized forms of cellular activation
[13]. Interestingly, previous research showed that metabolic
disturbances were associated with late-life depression especially
in men. In the same Health ABC cohort, Vogelzangs et al. [22]
reported that visceral fat was a risk factor for depression onset in
older men. In a subsequent study [23] we showed that leptin
dysregulation may represent an underlying mechanism for this
relationship. In a recent study [24] based on a large sample
including also patients with clinical diagnoses of depressive
disorders, elevated inflammation was confirmed in depressed
men, especially those with a late-onset depression. It is possible
that in late-life depression metabolic-related oxidative injuries may
have a larger role in men than in women. However, sex-specific
differences in depression-related immuno-metabolic markers have
not been found by all studies, and meta-analyses [42] including
also younger samples showed a less clear moderation role for sex.
Epidemiological studies on aging found gender-specific associa-
tions also with other biomarkers, such as plasma level of brain
derived neurotrophic factor and personality traits linked to
depression [45], although it is unknown whether this may have
a relationship with oxidative stress. Moreover, in women
depression may have a more complex etiology with other non-
biological factors (e.g. social support, stressful life events) [46;47]
playing stronger roles. Finally, the present study may have been
underpowered to detect an association in women. Nevertheless,
the above hypotheses are merely speculative and the sex-specificity
of the present findings needs confirmation in future research.
Several mechanisms could explain the relationship between
oxidative damage and depression. Neurons strongly depend on
mitochondrial oxidative phosphorlation for energy, and unbal-
anced generation of ROS in the electrons transport chain may
lead to oxidative damage, excitotoxicity and finally apoptosis.
Because of its high oxidizable lipid content brain is highly affected
by lipid peroxidation, which causes collapse of mitochondrial
membranes [4]. The 8-iso-PGF2a is indeed formed from
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peroxidation of arachidonic acid contained in phospholipids of cell
membranes and its formation contribute to alterations in fluidity
and integrity of membranes [13;48]. Furthermore, it has been
demonstrated that isoprostanes have biological activities that may
contribute to the progression of vascular damage inducing
leukocyte adhesion and endothelial and platelet activation [49].
This is consistent with the well-established association between
depression and cardiovascular diseases and the vascular hypothesis
of depression suggesting that vascular damage in the brain
predisposes to late-onset depression [50]. Oxidative stress might
also trigger, trough activation of Nuclear Factor kB transcription
activity, glia-mediated inflammatory responses linked to depres-
sion [4;42]. In this context, it is interesting to note the role of
antioxidants in the reduction of lipid peroxidation by quenching
free radicals. We recently showed [51] that low concentrations of
serum carotenoids, powerful antioxidants embedded within the
lipid layers that make up cell membranes, are associated with a
higher risk of depression onset; this association was partially
mediated by inflammation reduction. Moreover, it has been
shown that stress-related adrenal glucorticoids (e.g. cortisol), whose
alteration is considered an hallmark of some depressive syndromes,
increase the vulnerability of hippocampal neurons to metabolic
insult via impairment of antioxidant capacity [52–54]. Finally,
oxidative damage may also be the consequence of depression, due
to the fact that depression impacts health-related lifestyle such
physical activity, diet, obesity and smoking all of which have been
linked to oxidative stress [13]. However, in the present study
adjusting for behavioral factors did not attenuate the association
between 8-iso-PGF2a and depressed mood. The effect of
antidepressant treatment on oxidative stress markers has been
examined in only a few studies with mixed results. Treatment with
selective serotonin reuptake inhibitors has been shown to improve
lipid peroxidation and to normalize initially disturbed antioxidant
levels in depressed patients [55]. An in-vitro study [56] showed
that tricyclic antidepressants increased generation of reactive
oxygen species and decreased intracellular antioxidants; these
effects were not produced by monoamine-oxidase inhibitors.
Our study has some important strengths, such as a large sample
size, assessment of multiple confounders and the ability to test for
sex and race differences. At the same time, some limitations are
needed to be mentioned. First, since the study design is cross-
sectional no inference about the directionality of the association
can be made. Our analyses are based on single time-point
assessments of the studied biomarker which may not be sufficient
to adequately represent the participants’ true underlying metabolic
state. Information on specific medications that are believed to
lower urinary creatinine levels (e.g. Cephalosporins, Cimetidine,
Cisplatin, Gentamicin, Trimethoprim) was not available. In
addition, depression was not confirmed by a clinical diagnosis.
In fact, depressed mood was operationally defined by GDS-15
scores and use of antidepressants. Given the very low prevalence of
participants with depressed mood and the narrow variability of
GDS-15 scores, we were unable to perform sensitivity analyses
separating these two elements or using continuous GDS-15 scores.
However, participants on antidepressants may represent the most
severe case of depression (i.e., confounding by indication) and
indeed in our sample those on antidepressants had significantly
higher depressive symptoms.
Oxidative stress may represent one of the underlying mecha-
nism linking late-life depression with negative health outcomes. A
growing body of small clinical studies reported an association
between oxidative damage markers and depression [15–21]. Our
study adds to this growing literature by showing evidence for this
association in a large sample of older persons from the general
population. These findings underline the need for further studies
in larger samples, well characterized in terms of psychiatric
diagnoses and including measures of oxidative damage, in order to
test whether oxidative stress is a cause, result or epiphenomenon of
late-life depression and whether the modulation of oxidative stress
may break down the link between depression and its deleterious
health consequences.
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Table 2. Odds ratios (and 95% confidence intervals) of depressed mood according to 8-iso-PGF2a concentrations.
Association with Depressed Mood
Model 1 Model 2 Model 3
OR 95% CI p OR 95% CI p OR 95% CI p
Men (prevalence depressed mood 3.0%)
8-iso-PGF2a continuous
a 2.00 (1.12–3.56) 0.02 1.89 (1.05–3.42) 0.04 2.06 (1.09–3.89) 0.03
8-iso-PGF2a high (Q4) vs low (Q1-Q3)
b 2.55 (1.24–5.25) 0.01 2.40 (1.16–4.98) 0.02 2.61 (1.21–5.62) 0.01
Women (prevalence depressed mood 5.5%)
8-iso-PGF2a continuous
a 0.93 (0.60–1.45) 0.76 0.87 (0.56–1.36) 0.54 0.87 (0.56–1.36) 0.53
8-iso-PGF2a high (Q4) vs ow (Q1–Q3)
b 0.80 (0.40–1.57) 0.51 0.75 (0.38–1.49) 0.41 0.73 (0.36–1.46) 0.37
a8-iso-PGF2a. log-transformed.
b8-iso-PGF2a. High levels (sex-specific highest quartile): .926.7 pg/mg-creatinine in men and .1,175.4 pg/mg-creatinine in women.
Abbreviations: OR, Odds Ratio; 95%CI, 95% Confidence interval.
Model 1: unadjusted.
Model 2: adjusted for age, race, education and site.
Model 3: additionally adjusted for alcohol use, smoking, Modified Mini Mental State Examination, physical activity, body mass index, cerebrovascular diseases,
cardiovascular disease and diabetes.
doi:10.1371/journal.pone.0065406.t002
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LF SK BP.
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